Advanced Medical Nutrition Therapy - II Comprehensive Study Guide

FNC507A Medical Nutrition Therapy - II: Course Summary and Outcomes

  • Programme: M.Sc. Food Nutrition and Dietetics
  • Department: Food Technology (Faculty of Life and Allied Health Sciences)
  • Course Leader: Dr. Bhavana S
  • Course Aim: To provide an evidence-based medical approach to screening, assessing, and treating various medical conditions including Morbid Obesity, Eating Disorders, Diabetes Mellitus, Renal Diseases, PCOS, Thyroid Disorders, Cardiovascular Diseases (CVDs), Cancer, and HIV/AIDS.
  • Learning Outcomes:
    • Understand the preventive and therapeutic roles of diet in chronic degenerative diseases.
    • Analyze etiology, diagnosis, and pathophysiology of non-communicable diseases (NCDs).
    • Recommend nutritional care based on pathophysiology and prevent diet-related disorders.
    • Understand advances in emerging modes of therapy and ongoing field research.

Unit I: Medical Nutrition Therapy for Obesity and Weight Management

  • Definitions:
    • Obesity: A treatable disease and worldwide health concern associated with an excess amount of body fat.
    • WHO Definition: Abnormal or excessive fat accumulation that presents a risk to health.
    • BMI (Body Mass Index): A weight-for-height index calculated as weight(kg)/height(m)2weight(kg) / height(m)^2.
      • Overweight: BMI≥25.0 kg/m2BMI \ge 25.0\,kg/m^2
      • Obesity: BMI≥30.0 kg/m2BMI \ge 30.0\,kg/m^2
    • Childhood Obesity: For children under 5, overweight is >2> 2 standard deviations (SD) above the WHO median; obesity is >3> 3 SD above the median.
  • Types of Obesity:
    1. Developmental Obesity: Begins early in life, continuing into adulthood. Fat cells become saturated; foundation set by age 4. Results in higher lean body mass along with fat due to skeletal support for weight.
    2. Reactive Obesity: Develops due to emotional stress periods. Weight reflects intermittent ups and downs. Results in more lean mass relative to fat content.
  • Physiological & Genetic Factors:
    • Genes: The obob gene (produces leptin, the satiety hormone) and the β3\beta3-adrenoreceptor gene (located in adipose tissue, regulates resting metabolic rate and fat oxidation). Mutations in either can lead to weight gain.
    • Adipose Tissue:
      • WAT (White Adipose Tissue): The body’s energy reserve; stores fat, cushions organs, and acts as insulation.
      • BAT (Brown Adipose Tissue): The body’s heat generator; burns calories for thermogenesis.
  • Hormonal Regulation:
    • Leptin: Satiety hormone produced by fat cells. Obese individuals often face leptin resistance.
    • Ghrelin: Hunger hormone produced by the stomach; stimulates appetite.
    • Adiponectin: Regulates glucose and insulin sensitivity; levels are lower in obese individuals.
  • Assessment Methods:
    • Waist Circumference: High risk is >102 cm> 102\,cm for men and >88 cm> 88\,cm for women (>90 cm> 90\,cm and >80 cm> 80\,cm for Asian males/females respectively).
    • Waist-Hip Ratio (WHR): Indicator of abdominal obesity if >1.0> 1.0 (men) or >0.85> 0.85 (women).
    • Android Obesity: Upper trunk/central fatness.
    • Gynoid Obesity: Lower trunk (hip/buttocks) fatness.
  • Weight Management Theories:
    • Plateau Effect: Weight loss slows as glycogen and water are lost, then extra muscle mass is lost, reducing the Resting Metabolic Rate (RMR).
    • Set-Point Theory: The point where weight loss stops unless nutritional intake or physical activity is changed.
    • Yo-yo Effect (Weight Cycling): Repeated losing and gaining. Regaining weight happens faster and losing it becomes harder over time.
  • Surgical Options (Bariatric Surgery): Indicated for BMI≥40BMI \ge 40 or BMI≥35BMI \ge 35 with comorbidities.
    • Gastric Bypass: Current gold standard; creates a tiny stomach pouch.
    • Gastroplasty: Using staples to create a small opening into the distal stomach.
    • Jejuno-ileal Bypass: Reduces the absorptive surface of small intestines.
    • Jaw Wiring: Permits only liquid intake via straw.
    • Liposuction: Cosmetic procedure involving aspiration of subcutaneous fat.
  • Underweight Management:
    • Definition: BMI<18.5 kg/m2BMI < 18.5\,kg/m^2 or 10−20% below10-20\%\,below average expected weight.
    • Etiology: Hyperthyroidism, malabsorption, or genetic predisposition.
    • MNT: Energy intake 500−1000 Kcal/day500-1000\,Kcal/day in excess of needs. Protein at 1.2 g/kg/day1.2\,g/kg/day. Fats at 30% of calories30\%\,of\,calories.

Unit II: Medical Nutrition Therapy for Cardiovascular Diseases (CVD)

  • Atherosclerosis: A slow, progressive disease where fatty deposits (plaque) thicken the intima (innermost coat of artery).
    • Ischemia: Inadequate oxygen supply due to reduced blood flow, causing Angina Pectoris (chest pain radiating to the left arm).
    • Phases of Atherosclerosis: Phase 1 (asymptomatic fatty streaks), Phase 2 (plaque rupture-prone), Phase 3 (acute with non-occlusive thrombus), Phase 4 (occlusive thrombus/MI), Phase 5 (fibrotic lesion).
  • Hypertension (HT): Called the "silent killer."
    • Systolic (SBP): Pressure during contraction (Lup).
    • Diastolic (DBP): Pressure during relaxation (Dup).
    • Classifications (ACC/AHA):
      • Normal: <120/80 mmHg< 120/80\,mmHg
      • Elevated: 120−129/<80 mmHg120-129 / < 80\,mmHg
      • Stage 1: 130−139/80−89 mmHg130-139 / 80-89\,mmHg
      • Stage 2: ≥140/90 mmHg\ge 140/90\,mmHg
      • Crisis: ≥180/120 mmHg\ge 180/120\,mmHg
  • Heart Failure (HF/CHF): The heart cannot pump enough blood to meet metabolic needs.
    • Cardiac Cachexia: Unintentional severe weight loss caused by heart failure; requires high-calorie intake.
    • MNT for Heart Failure: Small frequent meals; restrict sodium (1−2 g/day1-2\,g/day); restrict fluids only if edema is present.
  • Diagnostic Tools: ECG (electrical signals), Echocardiogram (ultrasound), Stress Test (Treadmill), and Coronary Angiography (iodine contrast X-ray).
  • Dietary Approaches:
    • DASH Diet: High in Potassium, Calcium, and Magnesium; limits sodium to 2300 mg/day2300\,mg/day.
    • Mediterranean Diet: Focuses on plant-based foods, Extra Virgin Olive Oil (EVOO), and moderate fish (Omega-3 fatty acids).
  • Inflammatory Markers: C-Reactive Protein (CRP) is a primary biomarker; high levels indicate systemic inflammation and higher cardiac risk.

Unit III: Medical Nutrition Therapy for Diabetes Mellitus

  • Definition: A group of diseases characterized by hyperglycemia resulting from insulin secretion/action defects.
    • Type 1 (IDDM): Autoimmune destruction of islet β\beta-cells; requires exogenous insulin.
    • Type 2 (NIDDM): Insulin resistance and relative insulin deficiency; linked to obesity/lifestyle.
    • Type 3 (MRDM): Malnutrition Related Diabetes Mellitus; common in developing countries for ages 15-30.
    • Gestational Diabetes (GDM): Diagnosed for the first time during pregnancy; increases risk for T2DM later.
  • Diagnosis Criteria (ADA):
    • Fasting Plasma Glucose (FPG): Diabetes at ≥126 mg/dL\ge 126\,mg/dL.
    • Oral Glucose Tolerance Test (OGTT/GTT): 2-hour value ≥200 mg/dL\ge 200\,mg/dL after 75g glucose.
    • HbA1C: Diabetes at ≥6.5%\ge 6.5\%.
  • Theories of Prognosis:
    • Thin-Fat Phenotype: Common in India/China; normal BMI but high body fat percentage.
    • Thrifty Gene Hypothesis: Genetic basis for efficient fat storage for survival during scarcity, now harmful in sedentary lifestyles.
    • Carbohydrate-Insulin Model (CIM): Postulates that processed carbs shift energy deposition to adipose tissue.
  • MNT & Management:
    • Protein: 10−15% of total calories10-15\%\,of\,total\,calories.
    • Fiber: 20−30 g/day20-30\,g/day (soluble fiber slows glucose absorption).
    • Glycemic Index (GI): Low (≤55\le 55), Medium (56−6956-69), High (≥70\ge 70).
    • Carbohydrate Counting: Matching insulin dose to carbohydrate intake. 1 carb exchange = 15 g15\,g of carbohydrate.
  • Acute Complications: Diabetic Ketoacidosis (DKA - fruity breath/ketones), Hypoglycemia (shakiness/sweating), and Diabetic Coma.

Unit IV: Medical Nutrition Therapy for Renal Disorders

  • Kidney Functions: Filtration (urine formation), Excretion (urea/uric acid), Endocrine (Erythropoietin for RBCs, Renin for BP, Calcitriol for Vitamin D activation).
  • Assessment: Glomerular Filtration Rate (GFR) is the ideal marker. Normal clearance is ≈125 ml/min\approx 125\,ml/min.
    • Albuminuria: Principal marker of kidney damage; protein in urine.
  • Diseases:
    • Glomerulonephritis: Inflammation of glomeruli often post-streptococcal infection. Require energy-dense, protein-sparing diet (30−40 Kcal/kg30-40\,Kcal/kg; 0.5−0.6 g/kg0.5-0.6\,g/kg protein initially).
    • Nephrotic Syndrome: Massive proteinuria and edema. Goal: correct protein deficiency and manage sodium (1−2 g/day1-2\,g/day).
    • AKI (Acute Kidney Injury): Sudden loss of excretory function. Treated as a medical emergency.
    • CKD (Chronic Kidney Disease): Progressive damage. Stage 5 is ESRD (End-Stage Renal Disease) where GFR<15 ml/minGFR < 15\,ml/min.
  • Dialysis Types:
    • Hemodialysis (HD): External filtering 3 days/week; requires 1.0−1.2 g/kg1.0-1.2\,g/kg protein.
    • Peritoneal Dialysis (PD): Uses the peritoneum as a filter; requires higher protein (1.2−1.3 g/kg1.2-1.3\,g/kg) due to losses in dialysate.

Unit V: Medical Nutrition Therapy for Thyroid and Related Disorders

  • Thyroid Hormones: Triiodothyronine (T3) and Thyroxine (T4). Iodine is vital for synthesis (150 μg/day150\,\mu g/day min).
  • HPT Axis: Hypothalamus (TRH) →\rightarrow Pituitary (TSH) →\rightarrow Thyroid (T3/T4) negative feedback loop.
  • OAT Axis: Relationship between Ovaries, Adrenal, and Thyroid glands.
  • Disorders:
    • Hypothyroidism: Underactive thyroid (e.g., Hashimoto’s disease - autoimmune). Symptoms: weight gain, cold intolerance, constipation.
    • Hyperthyroidism: Overactive thyroid (e.g., Graves’ disease - autoimmune). Symptoms: weight loss, bulging eyes (exophthalmos), heat intolerance.
  • PCOS (Polycystic Ovary Syndrome): Endocrine disorder in women featuring cysts, androgen excess, and insulin resistance. MNT focuses on low-GI diet and weight management.

Unit VI: Medical Nutrition Therapy for Cancer

  • Carcinogenesis Stages: Initiation (irreversible genetic mutation), Promotion (reversible growth/division), Progression (invasion), and Metastasis (spread to distant organs).
  • Food Carcinogens: Aflatoxins (moldy nuts), HCAs (charred meats), Nitrosamines (processed meats), and Acrylamide (burnt starchy foods).
  • Cancer Cachexia: Severe wasting of muscle and fat; hypermetabolic state with energy needs of 30−35 Kcal/kg/day30-35\,Kcal/kg/day.
  • MNT: High-protein (1.2−2.0 g/kg1.2-2.0\,g/kg), high-energy. Focus on phytonutrients (Curcumin in turmeric, Lycopene in tomatoes, Sulforaphane in broccoli).

Unit VII: Medical Nutrition Therapy for HIV and AIDS

  • HIV (Human Immunodeficiency Virus): Retrovirus targeting CD4+ T cells.
  • Stages: Stage 1 (Acute), Stage 2 (Latency), Stage 3 (Symptomatic), Stage 4 (AIDS: CD4<200 cells/mm3CD4 < 200\,cells/mm^3).
  • AIDS Wasting Syndrome: Unintentional weight loss >10%> 10\%, chronic diarrhea/weakness for >30> 30 days.
  • MNT:
    • Increase energy needs by 10−30%10-30\%.
    • Protein: 1.2−2.0 g/kg/day1.2-2.0\,g/kg/day.
    • Treatment: ART (Antiretroviral Therapy), formerly HAART.
  • Special Considerations: For women/children, focus on preventing mother-to-child transmission (PMTCT), managing breastfeeding (exclusive for 6 months if ART available), and supporting growth milestones.

Practicals & Assessment

  1. Interpretation of diagnostic biomarkers.
  2. Assessment and management of underweight and obesity.
  3. Diet planning for CVD using the DASH approach.
  4. Carbohydrate counting and low-carb recipes.
  5. Diet planning for T2DM and its long-term complications.
  6. Development of low sodium and potassium recipes.
  7. Nutritional management of renal diseases.
  8. Management for Hypothyroidism and PCOS.
  9. Dietary management for underweight Cancer/AIDS patients.
  10. Assessment Weightage: Midterm Exam (25%25\%), Assignment (25%25\%), Semester End Exam (50%50\%).